These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21538532)

  • 1. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".
    Schwarzschild MA; Marek K; Eberly S; Oakes D; Shoulson I; Jennings D; Seibyl J; Ascherio A;
    Mov Disord; 2011 Aug; 26(10):1864-8. PubMed ID: 21538532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide variant by serum urate interaction in Parkinson's disease.
    Nazeri A; Roostaei T; Sadaghiani S; Chakravarty MM; Eberly S; Lang AE; Voineskos AN
    Ann Neurol; 2015 Nov; 78(5):731-41. PubMed ID: 26284320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.
    Schwarzschild MA; Schwid SR; Marek K; Watts A; Lang AE; Oakes D; Shoulson I; Ascherio A; ; Hyson C; Gorbold E; Rudolph A; Kieburtz K; Fahn S; Gauger L; Goetz C; Seibyl J; Forrest M; Ondrasik J
    Arch Neurol; 2008 Jun; 65(6):716-23. PubMed ID: 18413464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex-dependent association of urate on the patterns of striatal dopamine depletion in Parkinson's disease.
    Baik K; Chung SJ; Yoo HS; Lee YH; Jung JH; Sohn YH; Lee PH
    Eur J Neurol; 2020 May; 27(5):773-778. PubMed ID: 31994785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uric acid relates to dopamine transporter availability in Parkinson's disease.
    Moccia M; Pappatà S; Erro R; Picillo M; Vitale C; Amboni M; Longo K; Palladino R; Barone P; Pellecchia MT
    Acta Neurol Scand; 2015 Feb; 131(2):127-31. PubMed ID: 25288358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
    J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis.
    Schwarz J; Linke R; Kerner M; Mozley PD; Trenkwalder C; Gasser T; Tatsch K
    Arch Neurol; 2000 Feb; 57(2):205-8. PubMed ID: 10681078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.
    ; Schwarzschild MA; Ascherio A; Casaceli C; Curhan GC; Fitzgerald R; Kamp C; Lungu C; Macklin EA; Marek K; Mozaffarian D; Oakes D; Rudolph A; Shoulson I; Videnovic A; Scott B; Gauger L; Aldred J; Bixby M; Ciccarello J; Gunzler SA; Henchcliffe C; Brodsky M; Keith K; Hauser RA; Goetz C; LeDoux MS; Hinson V; Kumar R; Espay AJ; Jimenez-Shahed J; Hunter C; Christine C; Daley A; Leehey M; de Marcaida JA; Friedman JH; Hung A; Bwala G; Litvan I; Simon DK; Simuni T; Poon C; Schiess MC; Chou K; Park A; Bhatti D; Peterson C; Criswell SR; Rosenthal L; Durphy J; Shill HA; Mehta SH; Ahmed A; Deik AF; Fang JY; Stover N; Zhang L; Dewey RB; Gerald A; Boyd JT; Houston E; Suski V; Mosovsky S; Cloud L; Shah BB; Saint-Hilaire M; James R; Zauber SE; Reich S; Shprecher D; Pahwa R; Langhammer A; LaFaver K; LeWitt PA; Kaminski P; Goudreau J; Russell D; Houghton DJ; Laroche A; Thomas K; McGraw M; Mari Z; Serrano C; Blindauer K; Rabin M; Kurlan R; Morgan JC; Soileau M; Ainslie M; Bodis-Wollner I; Schneider RB; Waters C; Ratel AS; Beck CA; Bolger P; Callahan KF; Crotty GF; Klements D; Kostrzebski M; McMahon GM; Pothier L; Waikar SS; Lang A; Mestre T
    JAMA; 2021 Sep; 326(10):926-939. PubMed ID: 34519802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease.
    Booij J; Tissingh G; Winogrodzka A; Boer GJ; Stoof JC; Wolters EC; van Royen EA
    Eur J Nucl Med; 1997 Jan; 24(1):68-71. PubMed ID: 9044880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
    Booij J; Speelman JD; Horstink MW; Wolters EC
    Eur J Nucl Med; 2001 Mar; 28(3):266-72. PubMed ID: 11315592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects.
    Kim HJ; Im JH; Yang SO; Moon DH; Ryu JS; Bong JK; Nam KP; Cheon JH; Lee MC; Lee HK
    J Nucl Med; 1997 Nov; 38(11):1703-11. PubMed ID: 9374337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
    Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
    Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease.
    Pak K; Shin HK; Kim EJ; Lee JH; Lyoo CH; Son J; Lee MJ
    Parkinsonism Relat Disord; 2018 Jun; 51():67-72. PubMed ID: 29510907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoking in Patients with Parkinson's Disease: preliminary striatal DaT-SPECT findings.
    Gigante AF; Defazio G; Niccoli Asabella A; Superbo M; Ferrari C; Liuzzi D; Iliceto G; Livrea P; Rubini G
    Acta Neurol Scand; 2016 Oct; 134(4):265-70. PubMed ID: 26659996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
    Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
    Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.